Heparin induced thrombocytopenia: a prospective study

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Heparin is a widely used anticoagulant.
• Heparin-induced thrombocytopenia (HIT) is a serious adverse effect.
• The precise mechanism of HIT remains under investigation.

Purpose of the Study:

• To prospectively investigate the incidence and mechanism of heparin-induced thrombocytopenia.
• To compare the occurrence of thrombocytopenia between bovine and porcine heparin.
• To elucidate the role of a heparin-dependent cofactor in HIT.

Main Methods:

• Prospective randomized study of 43 patients receiving bovine or porcine heparin.
• Serial blood sampling before, during, and after thrombocytopenia onset.
• In vitro studies of patient plasma on normal platelets with added heparin.

Main Results:

• Thrombocytopenia occurred in 11.6% of patients.
• Bovine heparin was associated with mild to moderate thrombocytopenia in four patients.
• Porcine heparin was associated with mild thrombocytopenia in one patient.
• Patient plasma induced platelet aggregation and serotonin release in vitro, dependent on heparin presence.
• These effects correlated with thrombocytopenia severity and resolved upon heparin cessation.

Conclusions:

• The findings strongly support a heparin-dependent cofactor, likely an antibody, as the cause of HIT.
• This prospective study provides novel insights into the pathophysiology of HIT.
• Understanding the mechanism of HIT is crucial for patient safety and treatment strategies.